Organization (Academic)
Iran University of Medical Sciences
ClinicalTrials.gov lists Iran University of Medical Sciences as lead sponsor of 25 trials. It has 13 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Iran University of Medical Sciences: 25 lead-sponsored trials and 1 legal-entity registration.
Disease areas (40)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Back Pain | 6 |
| Low Back Pain | 6 |
| Pain | 6 |
| COVID-19 | 2 |
| Graves Disease | 2 |
Showing 5 of 40 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 2 |
| 2015 | 2 |
Showing 10 of 13 years.
Prediction, not a registry value: median of 15 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; 1 of 6 predicted trials reach the 36-month horizon; registered median of 12 months across 11 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (13)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| PREDNISOLONE | Orbital Pseudotumor | Phase 3 | 1 |
| Triamcinolone + Betamethason | Orbital Pseudotumor | Phase 3 | 1 |
| Recombinant Human Erythropoietin | Optic Nerve Injuries | Phase 3 | 1 |
| ASTED | Hyperthyroidism | Phase 2/3 | 1 |
| ASTED | Graves Disease | Phase 2/3 | 1 |
Showing 5 of 13 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| PREDNISOLONE | 1 |
| SELENIUM | 1 |
| BEVACIZUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 64% hit target (n=11) | 25% on time (n=8) |
Journals published in (135)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Cephalalgia : an international journal of headache | 12 |
| Spine | 12 |
| Journal of bodywork and movement therapies | 10 |
| Journal of back and musculoskeletal rehabilitation | 9 |
| Manual therapy | 9 |
Showing 5 of 135 journals.
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Ministry of Health and Medical Education | Co sponsors trial with | 2 |
| Mashhad University of Medical Sciences | Co sponsors trial with | 1 |
| Isfahan University of Medical Sciences | Co sponsors trial with | 1 |
| Kermanshah University of Medical Sciences | Co sponsors trial with | 1 |
| Tabriz University of Medical Sciences | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (33)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-08-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-11-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 33 events.
Biomarker capability evidence (40)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCD4 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| ADAMTS13 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| CBS | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| CD46 | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
| CFH | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar) |
Showing 5 of 40 evidence rows.
Biomarkers this organization publishes on (413)
Shown in this order: most publications first.
Showing 5 of 413 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.